First patient undergoes Luxturna gene therapy on NHS
Jake Ternet, patient at Moorfields Eye Hospital was the first in the UK to receive the treatment.
Read More
Tag: voretigene neparvovec
EU OKs Novartis’ gene therapy Luxturna for rare retinal disease
Novartis’ Luxturna has been approved by regulators in Europe to treat a rare inherited condition that causes sight loss.
Read More
Novartis buys access to Spark’s vision loss therapy
Novartis has bought itself rights to Spark Therapeutic’s gene therapy for a certain type of vision loss, in a deal worth up to $170 million.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
